Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04446117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Study acronym: CONTACT-02
StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Dec 18, 2025v29
  2. Start date: Jun 30, 2020 to Oct 19, 2020 Primary endpoints revised (2) · Study sites: 279 to 280 · Secondary endpoints shortened, about 4 wordsv28 Show 3 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 279 to 280
    • Secondary endpoints shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Completion date: Aug 31, 2024 to Oct 16, 2026v27
  4. Primary completion date: Jun 30, 2023 to Apr 19, 2024v26
  5. Re-verified, no change to tracked fieldsv25
Show 23 earlier versionsHide 23 earlier versions
  1. Study sites: 273 to 279v24
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 580 to confirmed 575 · Study sites: 272 to 273v23 Show 2 more changesShow less
    • Enrollment target: estimated 580 to confirmed 575
    • Study sites: 272 to 273
  3. Study sites: 260 to 272v22
  4. Study sites: 259 to 260v21
  5. Study sites: 254 to 259v20
  6. Study sites: 253 to 254v19
  7. Primary completion date: Mar 30, 2022 to Jun 30, 2023 Study sites: 233 to 253 · Completion date: Jul 30, 2023 to Aug 31, 2024v18 Show 2 more changesShow less
    • Study sites: 233 to 253
    • Completion date: Jul 30, 2023 to Aug 31, 2024
  8. Study sites: 229 to 233v17
  9. Study sites: 207 to 229v16
  10. Study sites: 196 to 207v15
  11. Study sites: 186 to 196v14
  12. Study sites: 167 to 186v13
  13. Study sites: 165 to 167v12
  14. Study sites: 155 to 165v11
  15. Study sites: 138 to 155v10
  16. Study sites: 104 to 138v9
  17. Study sites: 62 to 104v8
  18. Study sites: 17 to 62v7
  19. Study sites: 15 to 17v6
  20. Study sites: 6 to 15v5
  21. Study sites: 2 to 6v4
  22. Study sites: 1 to 2v3
  23. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
Trial Details
NCT Number NCT04446117
Lead Sponsor Exelixis
Collaborators: Roche-Genentech, Takeda
Conditions Metastatic Prostate Cancer, Prostate Adenocarcinoma
Enrollment 575 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov